Zhejiang Cancer Hospital: Carcinoma, Hepatocellular trials

The registry lists 10 Carcinoma, Hepatocellular studies with Zhejiang Cancer Hospital as lead sponsor. 5 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 1Phase 2 7Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• SH-LPS System in Preoperative Planning for Liver ResectionNot yet recruitingNCT06911086Phase 2/3
• Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular CarcinomaRecruitingNCT06741020Phase 1/2
• Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular CarcinomaRecruitingNCT05971199Phase 2
• Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Phase 2
• Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05903456Phase 2
• Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular CarcinomaStatus unknownNCT05053386Not applicable
• Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCCStatus unknownNCT05007587Early Phase 1
• TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)Status unknownNCT04560751
• TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT04066543Phase 2
• Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical StudyStatus unknownNCT02702323Phase 2/3